Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...
Zacks Investment Research on MSN18h
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-TermFor new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...
Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...
Hosted on MSN1mon
Gilead Sciences sets aside $200 million to resolve HIV drug probeNEW YORK (Reuters) -Gilead Sciences set aside $200 million for ... drugmaker's promotional speakers program for HIV drugs. The Foster City, California-based company disclosed the potential ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.6% in the company’s quarterly ...
Since the publication of my first article on the Foster City, California-based company, "Gilead Sciences: Seriously Undervalued At Peak Pessimism," its stock price has risen more than 60% ...
HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...
with headquarters in Foster City, Calif. For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback